Osteoboost Health, today announced it has closed an $8 million financing round to scale manufacturing, expand clinical research, and broaden the commercial reach of the company's FDA-cleared medical device for low bone density. The round was led by Ambit Health Ventures, with participation from new investors including Emmeline Ventures and Disrupt Health Impact Fund, as well as existing investors Esplanade Ventures and Portfolia.

Osteoboost Health is a company that applies science and medical expertise to create better health outcomes for women and men at risk of osteoporosis and bone fractures. The company's first FDA-approved device, Osteoboost, is poised to become the new standard of care in treating postmenopausal osteopenia.